| Description | Memantine, an amantadine derivative with some dopaminergic effects, has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blocking NMDA receptors. |
| molecular weight | 179.3 |
| Molecular formula | C12H21N |
| CAS | 19982-08-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (278.86 mM) |
| References | 1. Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017 Aug 21;12(8):e0183586. 2. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. eCollection 2016. Review. PubMed PMID: 27757016; PubMed Central PMCID: PMC5055113. 3. Greig SL. Memantine ER/Donepezil: A Review in Alzheimer's Disease. CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-Review. PubMed PMID: 26519339. 4. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 201Review. PubMed PMID: 25860130; PubMed Central PMCID: PMC4393306. |